PAVmed

PAVmed ROA

The Return on Assets (ROA) of PAVmed (PAVM) as of Oct 21, 2026 is 1.03 %. In the previous year, Return on Assets (ROA) was 129.78 % — a change of -99.20% (lower).

ROA

1.03 %

YoY

-99.20%

Last updated:

In 2025, PAVmed's return on assets (ROA) was 1.03 %, a -99.20% increase from the 129.78 % ROA in the previous year.

The PAVmed ROA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

ROA
Date
ROA
Jan 1, 2018
-211.49 USD
Jan 1, 2019
-220.03 USD
Jan 1, 2020
-173.30 USD
Jan 1, 2021
-57.89 USD
Jan 1, 2022
-164.84 USD
Jan 1, 2023
-193.77 USD
Jan 1, 2024
129.78 USD
Jan 1, 2025
1.03 USD
The PAVmed ROA history
YEARROAYoY
1.03 %-99.20%
129.78 %-166.98%
-193.77 %+17.55%
-164.84 %+184.77%
-57.89 %-66.60%
-173.30 %-21.24%
-220.03 %+4.04%
-211.49 %-63.57%
-580.56 %-10.57%
-649.21 %+343.66%
-146.33 %+124.54%
-65.17 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

PAVmed Stock analysis

What does PAVmed do? PAVmed, Inc. generates revenue through the development and commercialization of medical devices including PortIO, a vascular access device without central venous system access or indwelling intravascular components, and CarpX, a percutaneous device for carpal tunnel syndrome treatment. The company also offers NextCath, a self-anchoring catheter eliminating the need for suturing or traditional anchoring methods, and DisappEAR, antibiotic-eluting resorbable ear tubes utilizing aqueous silk technology. Additional products include NextFlo, a disposable infusion system with variable flow resistors, and Caldus, a disposable tissue ablation device. Medical device companies and healthcare providers purchase these products for patient treatment and surgical procedures. The firm's product portfolio targets specific medical needs such as vascular access, orthopedic procedures, and ear treatments. PortIO serves patients requiring long-term vascular access without traditional central line risks. CarpX addresses carpal tunnel syndrome through minimally invasive procedures. DisappEAR provides a solution for ear tube insertion using resorbable technology, reducing the need for follow-up surgeries. NextCath streamlines catheter placement in medical settings. PAVmed's commercial strategy focuses on medical device companies and healthcare providers seeking innovative solutions for vascular access, orthopedic interventions, and ear care. The company's products are designed to improve patient outcomes while reducing procedural complexity and costs. By leveraging proprietary technologies like aqueous silk for DisappEAR, PAVmed differentiates its offerings in the medical device market. PAVmed is one of the most popular companies on Eulerpool.

ROA Details

Understanding PAVmed's Return on Assets (ROA)

PAVmed's Return on Assets (ROA) is a key performance indicator that measures the company's profitability in relation to its total assets. It is calculated by dividing the net income by the total assets. A higher ROA indicates efficient asset utilization to generate profits, reflecting managerial effectiveness and financial health.

Year-to-Year Comparison

Comparing PAVmed's ROA year-over-year provides insights into the company’s operational efficiency and asset utilization trends. An increasing ROA demonstrates enhanced asset efficiency and profitability, while a declining ROA can indicate operational or financial challenges.

Impact on Investments

Investors consider PAVmed's ROA as a crucial metric to evaluate the company’s profitability and efficiency. A higher ROA signifies that the company is effectively utilizing its assets to generate profits, making it a potentially attractive investment.

Interpreting ROA Fluctuations

Variations in PAVmed’s ROA can be attributed to changes in net income, asset purchases, or operational efficiencies. Analyzing these fluctuations assists in assessing the company's financial performance, management efficiency, and strategic financial positioning.

Frequently Asked Questions about PAVmed stock

Return on Assets (ROA) of PAVmed is 1.03 % in 2025.

Return on Assets (ROA) of PAVmed changed from 129.78 % to 1.03 %, representing a -99.20% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Return on Assets (ROA) PAVmed since 2006 – with annual values, charts, and detailed analysis.

Return on Assets, also known as ROA, is a financial metric used to measure a company's profitability. It is used to determine how effectively a company uses its assets to generate profits. It is also referred to as the ratio of net income to total assets. ROA is an important indicator of a company's overall financial performance as it measures the company's ability to generate more profit from the assets it employs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Return on Assets (ROA)'s PAVmed with sector peers and the industry average to assess whether it is attractive.

To evaluate Return on Assets (ROA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Return on Assets (ROA).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — PAVmed

All Key Metrics — PAVmed